NASDAQ:ABEO
Abeona Therapeutics Inc.
Abeona Therapeutics Inc.'s revenue was $5.8M in fiscal 2025. Free cash flow was −$84.3M, −1448.5% of revenue, and the diluted share count rose 61.1%.Summary generated from Abeona Therapeutics Inc.'s SEC filings. Latest annual report filed Mar 17, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$5.8M
Revenue growthn/a
Revenue, 5-yr CAGR−10.3%
Gross margin73.7%
Operating margin−1536.9%
Net margin1223.1%
ROIC−127.2%
Return on equity70.0%
Debt / equity0.13
Free cash flow−$84.3M
FCF margin−1448.5%
Share count change+61.1%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 3 | 1 | 4 | n/a | 6 |
| Operating income | −90 | −51 | −47 | −64 | −89 |
| Net income | −85 | −40 | −54 | −64 | 71 |
| Free cash flow | −70 | −44 | −37 | −58 | −84 |
Recent filings
- 4Insider transaction report
Sep 29, 2026 - 4Insider transaction report
Sep 29, 2026 - 8-KRegulation FD disclosure
Sep 15, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 13, 2026 - 8-KResults of operations and financial condition
Aug 13, 2026 - 8-KResults of a shareholder vote
Jun 12, 2026 - 8-KDirector or officer change
Jun 12, 2026 - 8-KRegulation FD disclosure
Jun 10, 2026